Drug Profile
SR 58572A
Alternative Names: SR 585398Latest Information Update: 22 Sep 2004
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Beta-adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 30 Aug 1999 No development reported for Spasm in Italy (unspecified route)
- 25 Jul 1994 Investigation in Spasm in Italy (unspecified route)